SCHEMBL6044498

SCHEMBL6044498

COCCCOc1cc(Br)ccc1OCCCOCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.47
▸ SLC6A4 P31645 3/20 0.45
▸ HTR2C P28335 2/20 0.44
▸ HTR2B P41595 2/20 0.44
▸ HTR6 P50406 1/20 0.43
▸ CCR5 P51681 2/20 0.43
▸ USP2 O75604 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ RAB9A P51151 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21042791 0.92 SLC6A4 (0.53) LMNASLC6A4HTR2CHTR2BCCR5
SCHEMBL20456336 0.92 SLC6A4 (0.53) LMNASLC6A4HTR2CHTR2BCCR5
SCHEMBL31053270 0.90 SLC6A4 (0.46) LMNASLC6A4HTR2CHTR2BHTR6
SCHEMBL31053305 0.90 SLC6A4 (0.46) LMNASLC6A4HTR2CHTR2BHTR6
SCHEMBL15726115 0.85 SLC6A4 (0.54) LMNASLC6A4HTR2CHTR2BCCR5
SCHEMBL16845882 0.81 TSHR (0.56) LMNAKDM4EKMT2AALDH1A1L3MBTL1
SCHEMBL17893778 0.78 L3MBTL1 (0.53) LMNAKDM4EKMT2ARAB9AL3MBTL1
SCHEMBL29521181 0.78 MAPT (0.50) LMNAKDM4EKMT2ARAB9AL3MBTL1
SCHEMBL842107 0.78 MAPT (0.50) LMNAKDM4EKMT2ARAB9AL3MBTL1
SCHEMBL21215156 0.77 L3MBTL1 (0.57) LMNAKDM4EKMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1266118-C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides NOVARTIS AG (CH) 2006-07-26 — — CN disclosed
US-20060160731-A1 Peptide nucleic acids BUCHARDT OLE 2006-07-20 — — US disclosed
US-20060154926-A1 Methods of treating alzheimer's disease using aryl alkanoic acid amides ELAN PHARMACEUTICALS, INC. 2006-07-13 — — US disclosed
CN-1550491-A Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides ��˹��ŵ�� 2004-12-01 — — CN disclosed
CN-1153759-C Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides ��˹��ŵ�� 2004-06-16 — — CN disclosed
US-20040059087-A1 Peptide nucleic acids BUCHARDT OLE (DK) 2004-03-25 — — US disclosed
WO-2003103653-A1 METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES ELAN PHARMACEUTICALS, INC. (US) 2003-12-18 — — WO disclosed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 — — EP disclosed
US-5705658-A HYPOTENSIVE AGENTS NOVARTIS CORPORATION (US) 1998-01-06 — — US disclosed
US-5654445-A INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-08-05 — — US disclosed
US-5646143-A FOR TREATING A VARIETY OF CONDITIONS CIBA-GEIGY CORPORATION (US) 1997-07-08 — — US disclosed
US-5627182-A RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS CIBA GEIGY CORPORATION (US) 1997-05-06 — — US disclosed
US-5606078-A ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-02-25 — — US disclosed
US-5559111-A HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren CIBA-GEIGY CORPORATION (US) 1996-09-24 — — US disclosed
CN-1117960-A Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides CIBA GEIGY AG (CH) 1996-03-06 — — CN disclosed
EP-0678514-A1 3,5-Disubstituted tetrahydrofuran-2-ones CIBA-GEIGY AG (CH) 1995-10-25 — — EP disclosed
EP-0678503-A1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities CIBA-GEIGY AG (CH) 1995-10-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160731-A1 Peptide nucleic acids RNGTT, POLM, POLRMT LMNA 713/4885SLC6A4 2409/4885HTR2C 4701/4885
US-20040059087-A1 Peptide nucleic acids RNGTT, POLM, POLRMT LMNA 713/4885SLC6A4 2409/4885HTR2C 4701/4885
US-20060154926-A1 Methods of treating alzheimer's disease using aryl alkanoic acid amides BACE1, APP, PSEN1 LMNA 2080/4885SLC6A4 2195/4885HTR2C 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback